Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Jan;47(1):27–33. doi: 10.1038/bjc.1983.3

Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

J R Muindi, D R Newell, I E Smith, K R Harrap
PMCID: PMC2011259  PMID: 6401427

Abstract

PMM is a water-soluble alternative to HMM. PMM has been administered as an intravenous infusion to 17 patients in a Phase I clinical trial. The dose-limiting toxicities were nausea and vomiting which were observed in all patients at 500 mg m-2 and above. The dose was not escalated above 1300 mg m-2 where nausea and vomiting were severe, prolonged (greater than 24 h) and poorly controlled by anti-emetics. Haematological, hepatic and renal toxicities were not observed. Neurological toxicity was not observed at low doses (less than 500 mg/m2) but could not be determined at higher doses due to intensive anti-emetic therapy. Pharmacokinetic studies (100-500 mg m-2) indicated that PMM plasma levels are dose-dependent and that the PMM disposition-phase half-life is prolonged in patients with abnormal liver function. It is concluded that the severe toxicity of PMM will limit the clinical utility of this compound and hence Phase II trials are not recommended.

Full text

PDF
27

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajani J. A., Cabanillas F. F., Bodey G. P. Phase I trial of pentamethylmelamine. Cancer Treat Rep. 1982 May;66(5):1227–1228. [PubMed] [Google Scholar]
  2. Ames M. M., Powis G., Kovach J. S., Eagan R. T. Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. Cancer Res. 1979 Dec;39(12):5016–5021. [PubMed] [Google Scholar]
  3. Benvenuto J. A., Stewart D. J., Benjamin R. S., Loo T. L. Pharmacology of pentamethylmelamine in humans. Cancer Res. 1981 Feb;41(2):566–569. [PubMed] [Google Scholar]
  4. Bonomi P. D., Mladineo J., Morrin B., Wilbanks G., Jr, Slayton R. E. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents. Cancer Treat Rep. 1979 Jan;63(1):137–138. [PubMed] [Google Scholar]
  5. Broggini M., Colombo T., D'Incalci M., Donnelli M. G., Gescher A., Garattini S. Pharmacokinetics of hexamethylmelamine and pentamethylmelamine in mice. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):669–672. [PubMed] [Google Scholar]
  6. Casper E. S., Gralla R. J., Lynch G. R., Jones B. R., Woodcock T. M., Gordon C., Kelsen D. P., Young C. W. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion. Cancer Res. 1981 Apr;41(4):1402–1406. [PubMed] [Google Scholar]
  7. Connors T. A., Cumber A. J., Ross W. C., Clarke S. A., Mitchley B. C. Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine. Cancer Treat Rep. 1977 Aug;61(5):927–928. [PubMed] [Google Scholar]
  8. Cumber A. J., Ross W. C. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem Biol Interact. 1977 Jun;17(3):349–357. doi: 10.1016/0009-2797(77)90097-7. [DOI] [PubMed] [Google Scholar]
  9. D'Incalci M., Bolis G., Mangioni C., Morasca L., Garattini S. Variable oral absorption of hexamethylmelamine in man. Cancer Treat Rep. 1978 Dec;62(12):2117–2119. [PubMed] [Google Scholar]
  10. Gad-el-Mawla N. M., Muggia F. M., Hamza M. R., El-Morsi B., Sherif M., Mansour M. A., Khafagy M., El-Sebai I. T. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26. Cancer Treat Rep. 1978 Jul;62(7):993–996. [PubMed] [Google Scholar]
  11. Gescher A., D'Incalci M., Fanelli R., Farina P. N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine. Life Sci. 1980 Jan 14;26(2):147–154. doi: 10.1016/0024-3205(80)90059-4. [DOI] [PubMed] [Google Scholar]
  12. Goldberg R. S., Griffin J. P., McSherry J. W., Krakoff I. H. Phase I study of pentamethylmelamine. Cancer Treat Rep. 1980;64(12):1319–1322. [PubMed] [Google Scholar]
  13. Goldin A., Venditti J. M., Macdonald J. S., Muggia F. M., Henney J. E., Devita V. T., Jr Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer. 1981 Feb;17(2):129–142. doi: 10.1016/0014-2964(81)90027-x. [DOI] [PubMed] [Google Scholar]
  14. Ihde D. C., Dutcher J. S., Young R. C., Cordes R. S., Barlock A. L., Hubbard S. M., Jones R. B., Boyd M. R. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study. Cancer Treat Rep. 1981 Sep-Oct;65(9-10):755–762. [PubMed] [Google Scholar]
  15. Johnson B. L., Fisher R. I., Bender R. A., DeVita V. T., Jr, Chabner B. A., Young R. C. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer. 1978 Nov;42(5):2157–2161. doi: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  16. Legha S. S., Slavik M., Carter S. K. Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer. 1976 Jul;38(1):27–35. doi: 10.1002/1097-0142(197607)38:1<27::aid-cncr2820380106>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  17. Morimoto M., Green D., Rahman A., Goldin A., Schein P. S. Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice. Cancer Res. 1980 Aug;40(8 Pt 1):2762–2767. [PubMed] [Google Scholar]
  18. Omura G. A., Broun G. O., Papps J., Birch R. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1027–1029. [PubMed] [Google Scholar]
  19. Rutty C. J., Abel G. In vitro cytotoxicity of the methylmelamines. Chem Biol Interact. 1980 Feb;29(2):235–246. doi: 10.1016/0009-2797(80)90036-8. [DOI] [PubMed] [Google Scholar]
  20. Rutty C. J., Connors T. A. In vitro studies with hexamethylmelamine. Biochem Pharmacol. 1977 Dec 15;26(24):2385–2391. doi: 10.1016/0006-2952(77)90446-4. [DOI] [PubMed] [Google Scholar]
  21. Rutty C. J., Newell D. R., Muindi J. R., Harrap K. R. The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse. Cancer Chemother Pharmacol. 1982;8(1):105–111. doi: 10.1007/BF00292880. [DOI] [PubMed] [Google Scholar]
  22. Van Echo D. A., Chiuten D. F., Whitacre M., Aisner J., Lichtenfeld J. L., Wiernik P. H. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Cancer Treat Rep. 1980;64(12):1335–1339. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES